BRIEF—Idorsia maintains collab with ReveraGen after Phase II data

Swiss biotech Idorsia has maintained a collaboration with ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator under investigation for Duchenne Muscular Dystrophy (DMD).

The firm says it made the decision based on the report from a Phase IIa study, and will pay $15 million to maintain the agreement.

The collaboration will also be restructured to make milestone payments more dependent on commercial success. Idorsia now has an option on exclusive global rights to vamorolone, which could be worth tens of millions of dollars to ReveraGen.